Correlation between telomere length and efficacy of oral and long-acting injectable antipsychotics on severity and cognitive impairment of schizophrenia

References

• Bilder RM, Goldman RS, Volavka J, Czobor P, Hoptman M, Sheitman B, Lindenmayer J-P, Citrome L, McEvoy J, Kunz M, et al. 2002. Neurocognitive effects of clozapine, olanzapine, risperidone, and haloperidol in patients with chronic schizophrenia or schizoaffective disorder. Am J Psychiatry. 159(6):1018–1028. doi:10.1176/appi.ajp.159.6.1018
   PubMed Web of Science ®Google Scholar
• Bilder RM, Turkel E, Lipschutz-Broch L, Lieberman JA. 1992. Antipsychotic medication effects on neuropsychological functions. Psychopharmacol Bull. 28(4):353–366.
   PubMedGoogle Scholar
• Blasco MA. 2007. Telomere length, stem cells and aging. Nat Chem Biol. 3(10):640–649. doi:10.1038/nchembio.2007.38
   PubMed Web of Science ®Google Scholar
• Blyler CR, Gold JM. 2000. Cognitive effects of typical antipsychotic treatment: another look. In: Sharma T, Harvey PD, editors. Cognition in Schizophrenia. New York: Oxford University Press; p. 241–265.
   Google Scholar
• Brissos S, Veguilla MR, Taylor D, Balanzá-Martinez V. 2014. The role of long-acting injectable antipsychotics in schizophrenia: a critical appraisal. Ther Adv Psychopharmacol. 4(5):198–219. doi:10.1177/2045125314540297
   PubMedGoogle Scholar
• Buchanan RW, Holstein C, Breier A. 1994. The comparative efficacy and long-term effect of clozapine treatment on neuropsychological test performance. Biol Psychiatry. 36(11):717–725. doi:10.1016/0006-3223(94)90082-5
   PubMed Web of Science ®Google Scholar
• Cassens G, Inglis AK, Appelbaum PS, Gutheil TG. 1990. Neuroleptics: effects on neuropsychological function in chronic schizophrenic patients. Schizophr Bull. 16(3):477–499. doi:10.1093/schbul/16.3.477
   PubMed Web of Science ®Google Scholar
• Cawthon RM. 2002. Telomere measurement by quantitative PCR. Nucleic Acids Res. 30(10):25–31.
   Web of Science ®Google Scholar
• Charlson FJ, Ferrari AJ, Santomauro DF, Diminic S, Stockings E, Scott JG, McGrath JJ, Whiteford HA. 2018. Global epidemiology and burden of schizophrenia: findings from the global burden of disease study 2016. Schizophr Bull. 44(6):1195–1203. doi:10.1093/schbul/sby058
   PubMed Web of Science ®Google Scholar
• Correll CU, Citrome L, Haddad PM, Lauriello J, Olfson M, Calloway SM, Kane JM. 2016. The use of long-acting injectable antipsychotics in schizophrenia: evaluating the evidence. J Clin Psychiatry. 77(suppl 3):1–24. doi:10.4088/JCP.15032su1
   PubMed Web of Science ®Google Scholar
• Fagiolini A, Rocca P, De Giorgi S, Spina E, Amodeo G, Amore M. 2017. Clinical trial methodology to assess the efficacy/effectiveness of long-acting antipsychotics: randomized controlled trials vs naturalistic studies. Psychiatry Res. 247:257–264. doi:10.1016/j.psychres.2016.11.044
   PubMed Web of Science ®Google Scholar
• Green MF, Marshall BD, Wirshing WC, Ames D, Marder SR, McGurk S, Kern RS, Mintz J. 1997. Does risperidone improve verbal working memory in treatment-resistant schizophrenia? Am J Psychiatry. 154(6):799–804.
   PubMed Web of Science ®Google Scholar
• Green MF. 2002. Recent studies on the neurocognitive effects of second-generation antipsychotic medications. Curr Opin Psychiatry. 15(1):25–29. doi:10.1097/00001504-200201000-00005
   Web of Science ®Google Scholar
• Grimaldi-Bensouda L, Rouillon F, Astruc B, Rossignol M, Benichou J, Falissard B, Limosin F, Beaufils B, Vaiva G, Verdoux H, et al. 2012. Does long-acting injectable risperidone make a difference to the real-life treatment of schizophrenia? Results of the Cohort for the General study of Schizophrenia (CGS). Schizophr Res. 134(2-3):187–194. doi:10.1016/j.schres.2011.10.022
   PubMed Web of Science ®Google Scholar
• Harvey PD, Napolitano JA, Mao L, Gharabawi G. 2003. Comparative effects of risperidone and olanzapine on cognition in elderly patients with schizophrenia or schizoaffective disorder. Int J Geriatr Psychiatry. 18(9):820–829. doi:10.1002/gps.929
   PubMed Web of Science ®Google Scholar
• Hill SK, Bishop JR, Palumbo D, Sweeney JA. 2010. Effect of second-generation antipsychotics on cognition: current issues and future challenges. Expert Rev Neurother. 10(1):43–57. doi:10.1586/ern.09.143
   PubMed Web of Science ®Google Scholar
• Huhn M, Nikolakopoulou A, Schneider-Thoma J, Krause M, Samara M, Peter N, Arndt T, Bäckers L, Rothe P, Cipriani A, et al. 2019. Comparative efficacy and tolerability of 32 oral antipsychotics for the acute treatment of adults with multi-episode schizophrenia: a systematic review and network meta-analysis. Lancet. 394(10202):939–951. doi:10.1016/S0140-6736(19)31135-3
   PubMed Web of Science ®Google Scholar
• Kane J, Honigfeld G, Singer J, Meltzer H. 1988. Clozapine for the treatment-resistant schizophrenic. A double-blind comparison with chlorpromazine. Arch Gen Psychiatry. 45(9):789–796. doi:10.1001/archpsyc.1988.01800330013001
   PubMed Web of Science ®Google Scholar
• Kane JM, Eerdekens M, Lindenmayer JP, Keith SJ, Lesem M, Karcher K. 2003. Long-acting injectable risperidone: efficacy and safety of the first long-acting atypical antipsychotic. Am J Psychiatry. 160(6):1125–1132. doi:10.1176/appi.ajp.160.6.1125
   PubMed Web of Science ®Google Scholar
• Kane JM, Kishimoto T, Correll CU. 2013. Assessing the comparative effectiveness of long-acting injectable vs. oral antipsychotic medications in the prevention of relapse provides a case study in comparative effectiveness research in psychiatry. J Clin Epidemiol. 66(8 Suppl):S37–S41. doi:10.1016/j.jclinepi.2013.01.012
   PubMed Web of Science ®Google Scholar
• Kazhungil F, Kumar KJ, Viswanath B, Shankar RG, Kandavel T, Math SB, Venkatasubramanian G, Reddy YC. 2017. Neuropsychological profile of schizophrenia with and without obsessive compulsive disorder. Asian J Psychiatr. 29:30–34. doi:10.1016/j.ajp.2017.04.004
   PubMed Web of Science ®Google Scholar
• Keefe RS, McEvoy JP, editors. 2001. Negative symptom and cognitive deficit treatment response in schizophrenia, First Edition. Washington, DC: American Psychiatric Press, Inc.
   Google Scholar
• Kishimoto T, Nitta M, Borenstein M, Kane JM, Correll CU. 2013. Long-acting injectable versus oral antipsychotics in schizophrenia: a systematic review and meta-analysis of mirror-image studies. J Clin Psychiatry. 74(10):957–965. doi:10.4088/JCP.13r08440
   PubMed Web of Science ®Google Scholar
• Kishimoto T, Robenzadeh A, Leucht C, Leucht S, Watanabe K, Mimura M, Borenstein M, Kane JM, Correll CU. 2014. Long-acting injectable vs oral antipsychotics for relapse prevention in schizophrenia: a meta-analysis of randomized trials. Schizophr Bull. 40(1):192–213. doi:10.1093/schbul/sbs150
   PubMed Web of Science ®Google Scholar
• Kota LN, Purushottam M, Moily NS, Jain S. 2015. Shortened telomere in unremitted schizophrenia. Psychiatry Clin Neurosci. 69(5):292–297. doi:10.1111/pcn.12260
   PubMed Web of Science ®Google Scholar
• Krishnadas R, Moore BP, Nayak A, Patel RR. 2007. Relationship of cognitive function in patients with schizophrenia in remission to disability: a cross-sectional study in an Indian sample. Ann Gen Psychiatry. 6(1):1–8. doi:10.1186/1744-859X-6-19
   PubMedGoogle Scholar
• Lambert T, Olivares JM, Peuskens J, DeSouza C, Kozma CM, Otten P, Crivera C, Jacobs A, Macfadden W, Mao L, et al. 2011. Effectiveness of injectable risperidone long-acting therapy for schizophrenia: data from the US, Spain, Australia, and Belgium. Ann Gen Psychiatry. 10(1):10. doi:10.1186/1744-859X-10-10
   PubMedGoogle Scholar
• Lee MA, Thompson PA, Meltzer HY. 1994. Effects of clozapine on cognitive function in schizophrenia. J Clin Psychiatry. 55 Suppl B:82–87.
   PubMed Web of Science ®Google Scholar
• Lu W, Zhang Y, Liu D, Songyang Z, Wan M. 2013. Telomeres-structure, function, and regulation. Exp Cell Res. 319(2):133–141. doi:10.1016/j.yexcr.2012.09.005
   PubMed Web of Science ®Google Scholar
• Malaspina D, Dracxler R, Walsh-Messinger J, Harlap S, Goetz RR, Keefe D, Perrin MC. 2014. Telomere length, family history, and paternal age in schizophrenia. Mol Genet Genomic Med. 2(4):326–331. doi:10.1002/mgg3.71
   PubMedGoogle Scholar
• Mansour H, Chowdari K, Fathi W, Elassy M, Ibrahim I, Wood J, Bamne M, Tobar S, Yassin A, Salah H, et al. 2011. Does telomere length mediate associations between inbreeding and increased risk for bipolar I disorder and schizophrenia? Psychiatry Res. 188(1):129–132.,. doi:10.1016/j.psychres.2011.01.010
   PubMed Web of Science ®Google Scholar
• Maurya PK, Rizzo LB, Xavier G, Tempaku PF, Ota VK, Santoro ML, Spíndola LM, Moretti PS, Mazzotti DR, Gadelha A, et al. 2018. Leukocyte telomere length variation in different stages of schizophrenia. J Psychiatr Res. 96:218–223. doi:10.1016/j.jpsychires.2017.10.016
   PubMed Web of Science ®Google Scholar
• Meltzer HY, McGurk SR. 1999. The effects of clozapine, risperidone, and olanzapine on cognitive function in schizophrenia. Schizophr Bull. 25(2):233–256. doi:10.1093/oxfordjournals.schbul.a033376
   PubMed Web of Science ®Google Scholar
• Nieratschker V, Lahtinen J, Meier S, Strohmaier J, Frank J, Heinrich A, Breuer R, Witt SH, Nöthen MM, Rietschel M, et al. 2013. Longer telomere length in patients with schizophrenia. Schizophr Res. 149(1-3):116–120. doi:10.1016/j.schres.2013.06.043
   PubMed Web of Science ®Google Scholar
• Owen MJ, Sawa A, Mortensen PB. 2016. Schizophrenia. Lancet. 388(10039):86–97. doi:10.1016/S0140-6736(15)01121-6
   PubMed Web of Science ®Google Scholar
• Park S-C, Choi MY, Choi J, Park E, Tchoe HJ, Suh JK, Kim YH, Won SH, Chung Y-C, Bae K-Y, et al. 2018. Comparative efficacy and safety of long-acting injectable and oral second-generation antipsychotics for the treatment of schizophrenia: a systematic review and meta-analysis. Clin Psychopharmacol Neurosci. 16(4):361–375. doi:10.9758/cpn.2018.16.4.361
   PubMed Web of Science ®Google Scholar
• Peng X, Ascher-Svanum H, Faries D, Conley RR, Schuh KJ. 2011. Decline in hospitalization risk and health care cost after initiation of depot antipsychotics in the treatment of schizophrenia. Clinicoecon Outcomes Res. 3:9.
   PubMedGoogle Scholar
• Peters L, Krogmann A, von Hardenberg L, Bödeker K, Nöhles VB, Correll CU. 2019. Long-acting injections in schizophrenia: a 3-year update on randomized controlled trials published January 2016-March 2019. Curr Psychiatry Rep. 21(12):124. doi:10.1007/s11920-019-1114-0
   PubMed Web of Science ®Google Scholar
• Polho GB, De-Paula VJ, Cardillo G, Dos Santos B, Kerr DS. 2015. Leukocyte telomere length in patients with schizophrenia: a meta-analysis. Schizophr Res. 165(2-3):195–200. doi:10.1016/j.schres.2015.04.025
   PubMed Web of Science ®Google Scholar
• Raghavan DV, Shanmugiah A, Bharathi P, Jeyaprakash R. 2016. P300 and neuropsychological measurements in patients with schizophrenia and their healthy biological siblings. Indian J Psychiatry. 58(4):454. doi:10.4103/0019-5545.196709
   PubMed Web of Science ®Google Scholar
• Rao S, Kota LN, Li Z, Yao Y, Tang J, Mao C, Jain S, Xu Y, Xu Q. 2016. Accelerated leukocyte telomere erosion in schizophrenia: evidence from the present study and a meta-analysis. J Psychiatr Res. 79:50–56. doi:10.1016/j.jpsychires.2016.04.010
   PubMed Web of Science ®Google Scholar
• Rao SL, Subbakrishna DK, Gopukumar K. 2004. NIMHANS neuropsychology battery-2004, manual. National Institute of Mental Health and Neurosciences,First Edition.Bangalore.
   Google Scholar
• Rizvi S, Raza ST, Mahdi F. 2014. Telomere length variations in aging and age-related diseases. Curr Aging Sci. 7(3):161–167. doi:10.2174/1874609808666150122153151
   PubMedGoogle Scholar
• Rosenheck RA, Krystal JH, Lew R, Barnett PG, Fiore L, Valley D, Thwin SS, Vertrees JE, Liang MH. 2011. Long-acting risperidone and oral antipsychotics in unstable schizophrenia. N Engl J Med. 364(9):842–851. doi:10.1056/NEJMoa1005987
   PubMed Web of Science ®Google Scholar
• Russo P, Prinzi G, Proietti S, Lamonaca P, Frustaci A, Boccia S, Amore R, Lorenzi M, Onder G, Marzetti E, et al. 2018. Shorter telomere length in schizophrenia: evidence from a real-world population and meta-analysis of most recent literature. Schizophr Res. 202:37–45. doi:10.1016/j.schres.2018.07.015
   PubMed Web of Science ®Google Scholar
• Savolainen K, Räikkönen K, Kananen L, Kajantie E, Hovatta I, Lahti M, Lahti J, Pesonen A-K, Heinonen K, Eriksson JG, et al. 2012. History of mental disorders and leukocyte telomere length in late adulthood: the Helsinki Birth Cohort Study (HBCS). J Psychiatric Res. 46(10):1346–1353. doi:10.1016/j.jpsychires.2012.07.005
   PubMed Web of Science ®Google Scholar
• Shah M, Parikh D, Karia S. 2018. Depot preparation in schizophrenia: Indian outlook. Ann Indian Psychiatry. 2(2):152. doi:10.4103/aip.aip_41_18
   Google Scholar
• Spohn HE, Strauss ME. 1989. Relation of neuroleptic and anticholinergic medication to cognitive functions in schizophrenia. J Abnormal Psychol. 98(4):367–380. doi:10.1037/0021-843X.98.4.367
   PubMed Web of Science ®Google Scholar
• Squassina A, Manchia M, Pisanu C, Ardau R, Arzedi C, Bocchetta A, Caria P, Cocco C, Congiu D, Cossu E, et al. 2020. Telomere attrition and inflammatory load in severe psychiatric disorders and in response to psychotropic medications. Neuropsychopharmacology. 45(13):2229–2238. doi:10.1038/s41386-020-00844-z
   PubMed Web of Science ®Google Scholar
• Subotnik KL, Casaus LR, Ventura J, Luo JS, Hellemann GS, Gretchen-Doorly D, Marder S, Nuechterlein KH. 2015. Long-acting injectable risperidone for relapse prevention and control of breakthrough symptoms after a recent first episode of schizophrenia: a randomized clinical trial. JAMA Psychiatry. 72(8):822–829. doi:10.1001/jamapsychiatry.2015.0270
   PubMed Web of Science ®Google Scholar
• Tiihonen J, Haukka J, Taylor M, Haddad PM, Patel MX, Korhonen P. 2011. A nationwide cohort study of oral and depot antipsychotics after first hospitalization for schizophrenia. Am J Psychiatry. 168(6):603–609. doi:10.1176/appi.ajp.2011.10081224
   PubMed Web of Science ®Google Scholar
• Tiihonen J, Wahlbeck K, Lönnqvist J, Klaukka T, Ioannidis JPA, Volavka J, Haukka J. 2006. Effectiveness of antipsychotic treatments in a nationwide cohort of patients in community care after first hospitalisation due to schizophrenia and schizoaffective disorder: observational follow-up study. BMJ. 333(7561):224. doi:10.1136/bmj.38881.382755.2F
   PubMed Web of Science ®Google Scholar
• Von Zglinicki T, Martin-Ruiz CM. 2005. Telomeres as biomarkers for ageing and age-related diseases. Curr Mol Med. 5(2):197–203. doi:10.2174/1566524053586545
   PubMed Web of Science ®Google Scholar
• Woodward ND, Purdon SE, Meltzer HY, Zald DH. 2005. A meta-analysis of neuropsychological change to clozapine, olanzapine, quetiapine, and risperidone in schizophrenia. Int J Neuropsychopharmacol. 8(3):457–472. doi:10.1017/S146114570500516X
   PubMed Web of Science ®Google Scholar
• Yu W-Y, Chang H-W, Lin C-H, Cho C-L. 2008. Short telomeres in patients with chronic schizophrenia who show a poor response to treatment. J Psychiatry Neurosci. 33(3):244–247.
   PubMed Web of Science ®Google Scholar